<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Trial Intelligence - Medium]]></title>
        <description><![CDATA[Beyond the protocols, this publication brings to life the people, technology, and ideas transforming how clinical trials are conducted — and how breakthroughs reach patients faster. - Medium]]></description>
        <link>https://medium.com/unblinded?source=rss----ee83fe4e5d42---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Trial Intelligence - Medium</title>
            <link>https://medium.com/unblinded?source=rss----ee83fe4e5d42---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 18:02:25 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/unblinded" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[22 Systems Per Study: Why BYOT Is the Fix Clinical Research Needs]]></title>
            <link>https://medium.com/unblinded/22-systems-per-study-why-byot-is-the-fix-clinical-research-need-a181abeab2da?source=rss----ee83fe4e5d42---4</link>
            <guid isPermaLink="false">https://medium.com/p/a181abeab2da</guid>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[life-sciences]]></category>
            <category><![CDATA[clinical-research]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[RealTime eClinical Solutions]]></dc:creator>
            <pubDate>Wed, 22 Oct 2025 12:21:17 GMT</pubDate>
            <atom:updated>2025-10-22T14:36:22.207Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>Innovation at the site level doesn’t need to get lost in sponsor red tape.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fESLKRe9PWkDk3nWDDxDNw.png" /></figure><p>Clinical research sites are speaking up.</p><p>On average, a single study now requires 22 separate technology systems for sites to manage, from sponsor portals and spreadsheets to binders, shared drives, and one-off vendor platforms.</p><p>Instead of helping, these disconnected tools create:</p><ul><li><strong>Redundant work. </strong>The same data entered multiple times.</li><li><strong>Training burdens</strong>. Staff constantly learning new systems.</li><li><strong>Compliance risks. </strong>Incomplete audit trails and scattered records.</li></ul><blockquote>A Tufts CSDD study found that site start-up delays account for up to 30% of total trial timelines, with nearly 40% of selected sites underperforming, often because of operational bottlenecks created by fragmented systems.</blockquote><p>The solution isn’t <em>more </em>software<em>.</em> It’s smarter software <em>strategy</em>. That’s where Bring Your Own Technology (BYOT)<strong> </strong>comes in.</p><h3>The BYOT Movement</h3><p>Instead of forcing sites to adopt sponsor-provided platforms they’re unfamiliar with, BYOT empowers them to use their own validated systems. The payoff is obvious:</p><ul><li>Sites work in platforms they already know.</li><li>Sponsors get cleaner data and faster start-up.</li><li>Patients experience smoother, more confident care.</li></ul><p>This isn’t just efficiency. It’s equity. Sites finally get a seat at the table and sponsors gain stronger partnerships in return.</p><blockquote>The future of trials won’t be built on fragments.</blockquote><p>It’ll be built on flexible, interoperable technology that reduces burden, not adds to it. BYOT is the reset our industry needs.</p><h3><strong>How It Works: Horizons of Adoption</strong></h3><p>The <a href="https://www.dtra.org/bring-your-own-technology">BYOT Playbook</a>, developed by DTRA and co-authored by co-authored by global technology and operations leaders from RealTime eClinical Solutions, GSK, Medable, Syneos Health, Bristol Myers Squibb, Medidata, Eli Lilly, and Mayo Clinic, envisions a phased rollout beginning with the most practical entry point.</p><p><strong>Horizon 1: eConsent</strong> <br>Sponsors approve sites’ validated eConsent systems, improving quality while reducing one of the most common FDA inspection findings.</p><p><strong>Horizon 2+: eSource, eISF, and Direct Data Capture (DDC)</strong> <br>Over time, BYOT expands to more complex systems, supported by interoperability standards such as CDISC ODM, USDM, and FHIR.</p><p>This hybrid model allows sites with validated tools to use them, while others can still rely on sponsor-provided systems.</p><h3><strong>The Compliance Dossier: Building Trust</strong></h3><p>A key element of BYOT is the Compliance Dossier, a reusable validation package documenting security, audit trails, regulatory alignment, and system readiness. Sponsors get the assurance they need without requiring sites to “revalidate” over and over again.</p><h3><strong>Overcoming Concerns</strong></h3><p>Naturally, sponsors worry about oversight, data quality, and regulatory consistency. The BYOT Playbook addresses these concerns with:</p><ul><li>Standardized validation requirements</li><li>Risk-based monitoring approaches</li><li>Interoperability standards for data exchange</li><li>Clear audit trail and access protocols</li></ul><p>These safeguards ensure BYOT strengthens compliance while removing unnecessary inefficiency.</p><h3><strong>Real-World Proof</strong></h3><p>We’re already seeing this vision come to life. Sites switching to RealTime have demonstrated that site-led technology can:</p><ul><li>Cut screening timelines from 7+ days to same-day contact</li><li>Improve time-to-first follow-up by 98%</li><li>Strengthen patient engagement and retention through integrated tools</li></ul><p>This is exactly what BYOT is designed to achieve — better outcomes for sponsors, sites, and patients.</p><h3><strong>What‘s Next?</strong></h3><p>The BYOT initiative is not “all or nothing.”</p><p>Instead, it introduces a hybrid model that balances sponsor accountability with site flexibility. It’s a practical, phased approach that acknowledges where sites are today while paving the way for a more interoperable and efficient future.</p><p>For sponsors, the message is clear: supporting BYOT now means stronger site partnerships, faster trial execution, and more reliable data.</p><p>For sites, it’s a chance to show sponsors the value of the technology investments they’ve already made.</p><p><em>This article was originally published on the RealTime eClinical Solutions blog and has been adapted for Medium. </em><a href="https://realtime-eclinical.com/2025/10/13/bring-your-own-technology-byot-the-future-of-site-led-technology-in-clinical-trials/"><em>Read the full version here</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a181abeab2da" width="1" height="1" alt=""><hr><p><a href="https://medium.com/unblinded/22-systems-per-study-why-byot-is-the-fix-clinical-research-need-a181abeab2da">22 Systems Per Study: Why BYOT Is the Fix Clinical Research Needs</a> was originally published in <a href="https://medium.com/unblinded">Trial Intelligence</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[“Best-in-Breed” Is Overrated. Here’s Why “All-in-One” Wins.]]></title>
            <link>https://medium.com/unblinded/best-in-breed-is-overrated-heres-why-all-in-one-wins-d75423d2589f?source=rss----ee83fe4e5d42---4</link>
            <guid isPermaLink="false">https://medium.com/p/d75423d2589f</guid>
            <category><![CDATA[clinical-research]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[technology-leadership]]></category>
            <category><![CDATA[saas]]></category>
            <category><![CDATA[technology]]></category>
            <dc:creator><![CDATA[RealTime eClinical Solutions]]></dc:creator>
            <pubDate>Tue, 14 Oct 2025 17:28:29 GMT</pubDate>
            <atom:updated>2025-10-14T17:28:29.771Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>Why fragmented tech stacks fail — and how unified systems are quietly winning the race in clinical research.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IcblD-fMlm2suDBa_JQV-Q.png" /></figure><h3>The Myth of “Best-in-Breed”</h3><p>Clinical research sites love the idea of “best-in-breed.” Pick the top system for eSource. The best vendor for eReg/eISF. Another one for CTMS.</p><p>On paper, it looks like you’re building the dream stack. In reality? You’re building chaos.</p><h3>The Cost of Complexity</h3><p>Six or more logins per study. Teams stuck toggling between platforms. Data scattered across systems that don’t talk. Frustrated Principal Investigators who are on the hook for compliance, but don’t have total visibility across their trials.</p><p>That’s not “best-in-breed.” That’s best in burnout.</p><h3>A Smarter Play</h3><p>The smarter play isn’t more vendors. It’s one system that does more.</p><p>When sites shift to a unified platform, what we call a Site Operations Management System (SOMS), things change:</p><ul><li>Less logins</li><li>Compliance, built right in</li><li>Real-time visibility across financials, patient recruitment, coordinator tasks, data capture, patient engagement, compliance, and even performance analytics.</li><li>Staff who actually have time to focus on patients instead of platforms.</li></ul><p>But <a href="https://realtime-eclinical.com/2024/11/13/what-is-a-site-operations-management-system-soms/">what exactly is a Site Operations Management System (SOMS)</a>? <strong>A</strong>nd why is it such a game-changer? This model brings together what were once disconnected systems — CTMS, eReg/eISF, eSource, participant engagement, and reporting — into one unified environment. That means no more silos, duplicate data entry, or scattered visibility. Instead, every study, task, and metric lives in one place, giving site leaders real-time insight across operations, compliance, and financial health.</p><p>That’s the beauty of SOMS. It transforms technology from a burden into a bridge, connecting your people, your processes, and your performance into one continuous flow of operational intelligence.</p><h3>Control What You Can</h3><p>Sponsors push systems down on sites. You can’t control that. But you <em>can</em> control your own house.</p><p>That’s the principle behind a new framework introduced by the Decentralized Trials &amp; Research Alliance (DTRA) and coauthored by industry leaders, <a href="https://www.dtra.org/bring-your-own-technology">Bring Your Own Technology (BYOT)</a>.</p><p>The idea is simple but transformative: sites should be empowered to use the validated tools they already know and trust within sponsor-funded trials. Still, site empowerment doesn’t mean site chaos. Even if you use your own technology, it shouldn’t be a patchwork of disconnected tools.</p><p>Sites that get this right are scaling faster, cutting costs, and delivering trials with less friction and more impact.</p><h3><strong>The Bottom Line</strong></h3><p>“Best-in-breed” is spin. What sites actually need is a foundation. A single source of truth. A complete Site Operations Management System.</p><p>Because the future of research isn’t about picking more tools. It’s about picking the right one that connects them all.</p><p><em>This article first appeared on the </em><a href="https://realtime-eclinical.com/2025/05/27/webinar-recap-best-in-breed-vs-all-in-one-the-single-eclinical-system-advantage/"><em>RealTime eClinical Solutions blog</em></a><em> and has been adapted for Medium.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d75423d2589f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/unblinded/best-in-breed-is-overrated-heres-why-all-in-one-wins-d75423d2589f">“Best-in-Breed” Is Overrated. Here’s Why “All-in-One” Wins.</a> was originally published in <a href="https://medium.com/unblinded">Trial Intelligence</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>